Consun Pharmaceutical Group Limited
HKEX:1681.HK
8.51 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,590.115 | 2,339.65 | 2,044.66 | 1,752.83 | 1,728.256 | 1,843.973 | 1,660.23 | 1,223.488 | 831.108 | 730.683 | 571.765 | 457.801 |
| Cost of Revenue
| 668.437 | 576.738 | 517.324 | 431.159 | 466.851 | 459.547 | 431.835 | 312.465 | 160.542 | 158.916 | 119.531 | 111.112 |
| Gross Profit
| 1,921.678 | 1,762.912 | 1,527.336 | 1,321.671 | 1,261.405 | 1,384.426 | 1,228.395 | 911.023 | 670.566 | 571.767 | 452.234 | 346.689 |
| Gross Profit Ratio
| 0.742 | 0.753 | 0.747 | 0.754 | 0.73 | 0.751 | 0.74 | 0.745 | 0.807 | 0.783 | 0.791 | 0.757 |
| Reseach & Development Expenses
| 108.535 | 117.539 | 102.16 | 83.657 | 75.377 | 67.937 | 45.07 | 38.154 | 31.287 | 27.475 | 20.827 | 0 |
| General & Administrative Expenses
| 315.599 | 322.504 | 279.956 | 203.067 | 161.486 | 176.527 | 163.497 | 141.666 | 122.946 | 114.126 | 77.692 | 50.721 |
| Selling & Marketing Expenses
| 852.206 | 771.96 | 620.041 | 542.93 | 539.204 | 561.537 | 540.264 | 374.365 | 259.043 | 230.971 | 177.926 | 135.496 |
| SG&A
| 1,167.805 | 1,061.971 | 881.954 | 775.36 | 771.037 | 738.064 | 703.761 | 516.031 | 381.989 | 345.097 | 255.618 | 186.217 |
| Other Expenses
| 3.292 | -4.049 | 7.87 | -3.662 | 0.483 | 1.049 | 0.311 | 0.455 | 0.053 | -0.001 | 0 | 0.452 |
| Operating Expenses
| 1,099.048 | 1,058 | 857.818 | 744.422 | 1,121.102 | 756.517 | 675.78 | 509.361 | 382.874 | 336.399 | 245.988 | 168.04 |
| Operating Income
| 884.967 | 715.408 | 660.182 | 550.127 | 496.379 | 655.325 | 533.432 | 398.45 | 293.929 | 235.463 | 205.834 | 181.028 |
| Operating Income Ratio
| 0.342 | 0.306 | 0.323 | 0.314 | 0.287 | 0.355 | 0.321 | 0.326 | 0.354 | 0.322 | 0.36 | 0.395 |
| Total Other Income Expenses Net
| -21.264 | 30.985 | 35.679 | 33.609 | -29.043 | -27.469 | 11.55 | 5.002 | 20.853 | 28.696 | 34.673 | -1.966 |
| Income Before Tax
| 863.703 | 746.393 | 695.861 | 583.736 | 133.663 | 616.699 | 544.982 | 403.452 | 314.782 | 264.159 | 210.462 | 179.062 |
| Income Before Tax Ratio
| 0.333 | 0.319 | 0.34 | 0.333 | 0.077 | 0.334 | 0.328 | 0.33 | 0.379 | 0.362 | 0.368 | 0.391 |
| Income Tax Expense
| 77.149 | 62.696 | 108.744 | 101.993 | 70.541 | 119.208 | 123.162 | 83.795 | 65.093 | 52.959 | 57.58 | 42.856 |
| Net Income
| 784.534 | 682.907 | 590.172 | 498.788 | 79.82 | 465.353 | 396.242 | 307.526 | 249.689 | 211.2 | 152.882 | 136.206 |
| Net Income Ratio
| 0.303 | 0.292 | 0.289 | 0.285 | 0.046 | 0.252 | 0.239 | 0.251 | 0.3 | 0.289 | 0.267 | 0.298 |
| EPS
| 0.99 | 0.86 | 0.74 | 0.61 | 0.094 | 0.54 | 0.46 | 0.32 | 0.25 | 0.21 | 0.2 | 0.14 |
| EPS Diluted
| 0.98 | 0.86 | 0.73 | 0.61 | 0.09 | 0.53 | 0.46 | 0.32 | 0.25 | 0.21 | 0.2 | 0.14 |
| EBITDA
| 963.056 | 785.888 | 728.71 | 618.789 | 566.355 | 723.708 | 597.46 | 437.521 | 312.518 | 250.693 | 218.148 | 192.742 |
| EBITDA Ratio
| 0.372 | 0.336 | 0.356 | 0.353 | 0.328 | 0.392 | 0.36 | 0.358 | 0.376 | 0.343 | 0.382 | 0.421 |